Taking this into account, H.C. Wainwright reiterated its Protalix BioTherapeutics Inc [PLX] rating to a Buy in a research note published on June 08, 2020; the price target was $11. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who remained covering the stock and in mid April has reiterated a ‘”a Buy”‘ rating for it. Rodman & Renshaw began covering PLX with “Buy” recommendation on April 04, 2016. Jefferies revised its rating on April 23, 2015. It rated PLX as “a Buy” which previously was an “a Hold”.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance Review of PLX
On Friday, Protalix BioTherapeutics Inc [AMEX:PLX] saw its stock unchanged to $1.80. Over the last five days, the stock has gained 6.51%. Protalix BioTherapeutics Inc shares have risen nearly 1.12% since the year began. Nevertheless, the stocks have risen 5.88% over the past one year. While a 52-week high of $1.90 was reached on 01/03/24, a 52-week low of $0.82 was recorded on 08/14/24. SMA at 50 days reached $1.3566, while 200 days put it at $1.2016.
Levels Of Support And Resistance For PLX Stock
The 24-hour chart illustrates a support level at 1.7600, which if violated will result in even more drops to 1.7200. On the upside, there is a resistance level at 1.8300. A further resistance level may holdings at 1.8600. The Relative Strength Index (RSI) on the 14-day chart is 70.73, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0821, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 11.54%. Stochastics %K at 88.46% indicates the stock is a selling.
How much short interest is there in Protalix BioTherapeutics Inc?
A steep rise in short interest was recorded in Protalix BioTherapeutics Inc stocks on 2024-10-31, dropping by 29024.0 shares to a total of 3.1 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 3.13 million shares. There was a decline of -0.94%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 12, 2014 when R. F. Lafferty resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $5.
